The current toolbox for APOBEC drug discovery

Michael J. Grillo, Katherine F.M. Jones, Michael A. Carpenter, Reuben S. Harris, Daniel A. Harki

Resultado de la investigación: Review articlerevisión exhaustiva

3 Citas (Scopus)

Resumen

Mutational processes driving genome evolution and heterogeneity contribute to immune evasion and therapy resistance in viral infections and cancer. APOBEC3 (A3) enzymes promote such mutations by catalyzing the deamination of cytosines to uracils in single-stranded DNA. Chemical inhibition of A3 enzymes may yield an antimutation therapeutic strategy to improve the durability of current drug therapies that are prone to resistance mutations. A3 small-molecule drug discovery efforts to date have been restricted to a single high-throughput biochemical activity assay; however, the arsenal of discovery assays has significantly expanded in recent years. The assays used to study A3 enzymes are reviewed here with an eye towards their potential for small-molecule discovery efforts.

Idioma originalEnglish (US)
Páginas (desde-hasta)362-377
Número de páginas16
PublicaciónTrends in Pharmacological Sciences
Volumen43
N.º5
DOI
EstadoPublished - may. 2022
Publicado de forma externa

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Huella

Profundice en los temas de investigación de 'The current toolbox for APOBEC drug discovery'. En conjunto forman una huella única.

Citar esto